(DD) DuPont de Nemours, Inc. Company Overview

What does DuPont de Nemours do after the Qnity separation?

DuPont de Nemours, Inc. is a NYSE-listed specialty materials and technology company trading under the ticker DD. The business that investors analyze in 2026 is more focused than the historical DuPont name suggests: after the electronics separation into Qnity and the Aramids divestiture, DuPont reports two continuing segments, Healthcare & Water Technologies and Diversified Industrials. The company describes itself as a provider of advanced solutions for healthcare, water, construction, and industrial markets in its first-quarter 2026 results.

A more focused specialty materials portfolio

The useful way to read DuPont is not as a commodity chemical company. Its continuing portfolio is built around materials, membranes, medical components, packaging substrates, adhesives, lubricants, construction solutions, and industrial technologies where product qualification, performance reliability, customer support, and process knowledge matter. The 2025 Form 10-K shows that continuing FY2025 net sales were $6.849 billion, a much cleaner base after divested or separated businesses were classified as discontinued operations.

Where DuPont products sit in customer value chains

DuPont sells inputs that are often small relative to the finished product cost but important to performance, compliance, uptime, or safety. TYVEK medical packaging protects sterile medical devices; FILMTEC and other water technologies help purify process and municipal water; adhesives and specialty lubricants support automotive, aerospace, and industrial applications. That position explains why the investment question is not only “how much volume can DuPont ship?” but also “where does it have specification power, technical service depth, and customer switching friction?”

How does DuPont make money?

DuPont makes money primarily by selling differentiated materials and engineered products to industrial, healthcare, water, and construction customers. Revenue is product revenue, but the pricing logic is closer to specialty materials than bulk chemicals: customers pay for performance, qualification history, technical service, reliability, brand recognition, and supply assurance. This is why DuPont’s margins depend on mix, productivity, raw-material inflation recovery, and the strength of demand in specific applications.

Product revenue, not commodity volume alone

A student building a business model canvas for DuPont should separate three value drivers. First is specification: products must meet technical and regulatory requirements, especially in medical, water, aerospace, and industrial applications. Second is service: DuPont supports customers through testing, formulation, application development, and local distribution. Third is portfolio discipline: the company has been exiting or separating assets that do not fit the focused specialty-materials profile.

Which segment is larger now?

In Q1 2026, Diversified Industrials was slightly larger by sales, while Healthcare & Water Technologies carried the higher margin. That distinction matters because a revenue-only analysis understates the importance of healthcare and water: $806 million of Q1 2026 sales produced $244 million of operating EBITDA, while $875 million of Diversified Industrials sales produced $200 million.

Which segments and geographies matter most?

DuPont’s post-electronics mix creates a strategic tension: the Healthcare & Water segment is smaller than Diversified Industrials by FY2025 revenue, but it is the margin leader. Diversified Industrials is broad, useful for diversification, and important to scale, yet it carries more construction and industrial-cycle exposure. For a DCF model, this means segment mix can matter as much as consolidated sales growth.

Healthcare & Water is the margin leader

Healthcare & Water generated FY2025 net sales of $3.233 billion and operating EBITDA of $972 million, an EBITDA margin of about 30.1%. The segment grew 9% in FY2025, helped by volume, currency, and portfolio effects. Its customer demand is tied to medical packaging, device components, biopharma, industrial water, municipal water, and purification applications.

Diversified Industrials carries the construction-cycle exposure

Diversified Industrials generated FY2025 net sales of $3.616 billion and operating EBITDA of $800 million, an EBITDA margin of about 22.1%. Management attributed the FY2025 sales decline to volume, price/mix, and portfolio effects, with weakness in building technologies tied to construction demand. The same segment also benefits from aerospace, automotive, consumer goods, and packaging applications, so it is not a single-cycle business.

What does DuPont's latest quarter show?

The latest official reporting period is Q1 2026, the quarter ended March 31, 2026. It shows a company improving margins and cash conversion while still absorbing costs from portfolio actions. Net sales grew 4% year over year to $1.681 billion, with 2% organic sales growth and 2% currency benefit. Operating EBITDA increased 15% to $414 million, and operating EBITDA margin expanded to 24.6%.

Growth came from organic sales, currency, mix, and productivity

The first quarter was not a simple volume acceleration story. Management reported 2% organic sales growth, with net sales also helped by currency. Healthcare & Water sales rose 6%, including 3% organic growth, while Diversified Industrials rose 3% with approximately flat organic sales. That mix explains why a small consolidated sales gain translated into better EBITDA growth.

Cash flow improved as separation costs moderated

Cash flow is important because DuPont is still simplifying its portfolio. In Q1 2026, the company reported $232 million of operating cash flow from continuing operations, $102 million of capital expenditures, and $147 million of transaction-adjusted free cash flow after adding back $17 million of separation-related and other payments. That 65% transaction-adjusted free-cash-flow conversion is a useful early signal for the cleaner portfolio.

What strategic turning points still shape DuPont today?

DuPont’s current analysis is inseparable from its portfolio restructuring. The name carries long industrial history, but the key investment facts are recent: the company has been narrowing its scope, separating electronics, selling aramids, and adding higher-value medical and water assets. These moves make the business easier to model, but they also create transition costs, stranded corporate expenses, and comparability issues across years.

1. 2017
   Dow and DuPont combined as DowDuPont, setting up a multi-company breakup rather than a permanent conglomerate.
2. 2019
   The materials-science separation created a new Dow, leaving DuPont as a more specialty-oriented business.
3. 2023
   DuPont acquired Spectrum Plastics, adding medical-device components in structural heart, electrophysiology, surgical robotics, and cardiovascular applications.
4. 2024
   The Donatelle acquisition expanded medical component and device design, development, and manufacturing capability.
5. 2025
   DuPont completed the separation of its electronics business into Qnity on November 1, 2025, distributing about 209 million Qnity shares to stockholders through a one-for-two distribution.
6. 2026
   DuPont completed the Aramids divestiture on April 1, 2026, receiving about $1.2 billion in pretax cash proceeds, a $300 million note receivable, and a non-controlling equity interest valued at $325 million.

From conglomerate breakup to focused advanced solutions

The Qnity separation is the biggest recent structural change. DuPont announced that Qnity Electronics became an independent company on November 1, 2025, with Qnity shares trading under ticker Q and DuPont continuing under ticker DD. The official Qnity separation announcement matters because electronics had different growth drivers, capital needs, and valuation comparables than the continuing DuPont portfolio.

Why the 2025-2026 portfolio reset matters

The Aramids transaction further reduced complexity. In the official Aramids divestiture announcement, DuPont said the sale included pretax cash proceeds of about $1.2 billion plus a note and equity consideration. For researchers, the point is not only proceeds. The transaction reclassified Aramids as discontinued operations and changed how historical sales, margins, and cash flows should be compared.

What gives DuPont a competitive advantage?

DuPont’s competitive advantage is strongest where the cost of product failure is high and the cost of switching is meaningful. The company’s 2025 Form 10-K says its markets are competitive, but also points to proprietary product and process technologies, application development pipelines, brands, technical and testing services, global manufacturing capability, and local service as supports for its competitive position. The same filing notes about 4,700 patents and patent applications associated with continuing operations at December 31, 2025, with more than 70% having a remaining term of more than five years.

Application know-how and qualification cycles

In healthcare, water, aerospace, and industrial reliability applications, customers do not change suppliers casually. A sterile packaging material, membrane, adhesive, lubricant, or process technology may require validation, documentation, regulatory alignment, and performance history. That creates switching friction. It does not eliminate competition, but it means DuPont’s moat is partly embedded in customer approval cycles rather than only in brand awareness.

The moat is strongest where failure costs are high

The company’s competitors include multinational and regional materials suppliers with significant sales, marketing, research, and financial resources. That means DuPont cannot rely on size alone. Its durable edge comes from a combination of intellectual property, customer intimacy, manufacturing reliability, product breadth, and application engineering. For MBA readers, this is a resource-based advantage: the valuable assets are not only factories, but also know-how, specifications, test data, brands, and customer relationships.

How financially strong is DuPont?

DuPont’s financial strength looks different depending on whether the reader focuses on GAAP net income, operating EBITDA, cash flow, or the balance sheet. FY2025 continuing net sales were $6.849 billion, operating EBITDA was about $1.63 billion, and transaction-adjusted free cash flow was $689 million. GAAP continuing income was only $98 million, while discontinued operations produced a loss, so normalized operating earnings give a better view of the continuing portfolio than headline net income.

Margins improved, but GAAP results still reflect portfolio cleanup

A useful margin calculation is operating EBITDA divided by net sales. For FY2025, operating EBITDA of about $1.63 billion on $6.849 billion of net sales implies a margin near 23.8%. In Q1 2026, operating EBITDA margin improved to 24.6%, while Healthcare & Water reached 30.3% and Diversified Industrials reached 22.9%. The margin story is therefore positive, but it must be read alongside restructuring charges and separation costs.

Debt moved down after separation

The balance sheet changed materially in FY2025. Total debt declined to $3.194 billion at December 31, 2025 from $7.171 billion a year earlier, while cash and equivalents declined to $715 million. The current ratio was about 1.87x, calculated from $3.719 billion of current assets and $1.991 billion of current liabilities. DuPont also disclosed no long-term debt due within one year at year-end 2025, with major maturities concentrated in 2028 and 2031 or later.

Capital allocation is now about focused reinvestment plus returns

Capital allocation after Qnity is about funding growth in medical, water, and specialty industrial markets while controlling separation costs and right-sizing the balance sheet. DuPont expected about $320 million of 2026 capital expenditures in its annual report. In Q1 2026, the company also raised full-year 2026 guidance to net sales of $7.155 billion to $7.215 billion, operating EBITDA of $1.730 billion to $1.760 billion, and adjusted EPS of $2.35 to $2.40.

Who owns DuPont stock, and what does governance signal?

DuPont has a conventional public-company ownership profile: no founder-control structure, no dual-class voting arrangement, and meaningful institutional influence. The 2026 proxy statement, filed with the SEC, reported 409,877,186 shares outstanding as of April 7, 2026. It also identified Vanguard and BlackRock as major holders, while directors and executive officers as a group beneficially owned less than 1% of shares. The 2026 DEF 14A proxy statement is the cleanest official source for this governance view.

Institutional ownership is influential, but not controlled

For investors, this means DuPont’s governance story is more about board oversight, incentive design, and institutional voting than about a controlling shareholder. In 2026, shareholders also approved a reverse stock split, and DuPont announced that every three shares would be combined into one share with authorized shares reduced from 1,666,666,667 to 555,555,556. The official reverse-stock-split announcement is mainly a share-structure event, not an operating-performance event.

Management incentives turned around the separation year

The proxy also shows how incentives reflected the unusual 2025 transition year. For Q1 through Q3 2025, the short-term incentive plan used adjusted EPS at 50%, organic revenue at 20%, adjusted operating EBITDA at 15%, and adjusted free cash flow at 15%. For Q4 2025, after separation, organic revenue was weighted at 100%. For 2026 long-term incentives, DuPont returned to a 60% performance-share-unit and 40% restricted-stock-unit mix, which puts more weight back on performance outcomes.

What opportunities and risks could change the story?

The upside case for DuPont is a cleaner, higher-margin company with growth in medical packaging, medical components, water technologies, and specialized industrial applications. The pressure case is that construction weakness, raw-material inflation, restructuring costs, trade restrictions, currency movements, or product-development delays dilute that improvement. The company’s risk disclosures are therefore not generic legal boilerplate; they map directly to revenue geography, operating margin, and cash-flow conversion.

Growth drivers to watch

The company’s stated outlook points to organic growth, pricing actions to offset input costs, medical and water demand, construction stabilization, and industrial recovery. Q1 2026 full-year guidance assumed about 4% organic growth, including about 1% pricing from actions intended to offset higher input costs. If Healthcare & Water continues to grow faster than Diversified Industrials, mix could support margins even if consolidated sales growth remains moderate.

Risks from filings: China, construction, regulation, separation execution

DuPont’s filings identify several concrete risks. International operations represented about 53% of FY2025 continuing net sales, exposing results to currency, geopolitical, and trade issues. China and Hong Kong represented about 10% of FY2025 consolidated net sales. The 10-K also notes environmental regulatory exposure, product development risk, competition for talent, credit-rating risk, and construction seasonality in North American Building Technologies. In the latest Form 10-Q, the company recorded $52 million of restructuring charges under a 2026 program expected to generate about $80 million of pre-tax charges through 2028.

Why does DuPont matter for valuation and research?

DuPont is a useful case study because the investment debate is about business quality after a portfolio reset. A DCF model should not treat the company as a simple sales-growth story. The key drivers are post-separation organic growth, Healthcare & Water mix, operating EBITDA margin, restructuring savings, cash-flow conversion after separation payments decline, capital expenditures, debt capacity, and the durability of technical customer relationships.

DCF drivers are mostly margin, reinvestment, and cycle risk

The most important model inputs are not hard to identify. Revenue growth should be split between organic volume, price, currency, and portfolio changes. Operating margin should be modeled by segment because a point of mix shift toward Healthcare & Water is not the same as a point of mix shift toward more cyclical construction applications. Free cash flow should distinguish reported operating cash flow from transaction-adjusted free cash flow until separation costs are no longer material.

What should a student, analyst, or investor conclude?

The cleanest takeaway is that DuPont is becoming a focused specialty-materials company with a higher-quality healthcare and water core, a broader but more cyclical industrial segment, and meaningful execution work still underway. Its 2026 story depends on whether the portfolio reset turns into sustained operating margin, cash flow, and capital-allocation clarity rather than one-time restructuring optics.